Paris, January 8, 2024 – Jeantet advised investment funds OrbiMed and Morningside Ventures in connection with the Series C financing of French biopharmaceutical company ENYO Pharma.

ENYO Pharma, a clinical-stage biopharmaceutical company developing proprietary medicines to improve quality of life and avoid end-stage renal failure and dialysis in patients with kidney disease, announced on January 3, 2024 a €39 million Series C, co-led by investment companies OrbiMed and Morningside, with the participation of the company’s historical shareholders.

ENYO also announced that it had received Investigational New Drug (IND) designation from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial on Vonafexor, a highly selective FXR agonist, for the treatment of Alport syndrome. This is a major milestone for ENYO.

Download the press release